Skip to main content
Erschienen in: Reviews in Endocrine and Metabolic Disorders 2/2018

06.10.2018

Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors

verfasst von: Sergio Pedraza-Arévalo, Manuel D. Gahete, Emilia Alors-Pérez, Raúl M. Luque, Justo P. Castaño

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Neuroendocrine tumors (NETs) comprise a complex and highly heterogeneous group of neoplasms that can arise all over the body, originating from neuroendocrine cells. NETs are characterized by a general lack of symptoms until they are in advanced phase, and early biomarkers are not as available and useful as required. Heterogeneity is an intrinsic, pivotal feature of NETs that derives from diverse causes and ultimately shapes tumor fate. The different layers that conform NET heterogeneity include a wide range of distinct characteristics, from the mere location of the tumor to its clinical and functional features, and from its cellular properties, to the core signaling and (epi)genetic components defining the molecular signature of the tumor. The importance of this heterogeneity resides in that it translates into a high variability among tumors and, hence, patients, which hinders a more precise diagnosis and prognosis and more efficacious treatment of these diseases. In this review, we highlight the significance of this heterogeneity as an intrinsic hallmark of NETs, its repercussion on clinical approaches and tumor management, and some of the possible factors associated to such heterogeneity, including epigenetic and genetic elements, post-transcriptional regulation, or splicing alterations. Notwithstanding, heterogeneity can also represent a valuable and actionable feature, towards improving medical approaches based on personalized medicine. We conclude that NETs can no longer be viewed as a single disease entity and that their diagnosis, prognosis and treatment must reflect and incorporate this heterogeneity.
Literatur
1.
Zurück zum Zitat Kloppel G, et al. Siegfried Oberndorfer: a tribute to his work and life between Munich, Kiel, Geneva, and Istanbul. Virchows Arch. 2007;451(Suppl 1):S3–7.PubMedCrossRef Kloppel G, et al. Siegfried Oberndorfer: a tribute to his work and life between Munich, Kiel, Geneva, and Istanbul. Virchows Arch. 2007;451(Suppl 1):S3–7.PubMedCrossRef
2.
Zurück zum Zitat Modlin IM, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.PubMedCrossRef Modlin IM, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.PubMedCrossRef
3.
Zurück zum Zitat Petersenn S, Koch CA. Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines. Rev Endocr Metab Disord. 2017;18(4):373–8.PubMedCrossRef Petersenn S, Koch CA. Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines. Rev Endocr Metab Disord. 2017;18(4):373–8.PubMedCrossRef
4.
Zurück zum Zitat Fraenkel M, Faggiano A, Valk GD. Epidemiology of neuroendocrine tumors. Front Horm Res. 2015;44:1–23.PubMedCrossRef Fraenkel M, Faggiano A, Valk GD. Epidemiology of neuroendocrine tumors. Front Horm Res. 2015;44:1–23.PubMedCrossRef
5.
Zurück zum Zitat Dasari A, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.PubMedPubMedCentralCrossRef Dasari A, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963;1(7275):238–9.PubMedCrossRef Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963;1(7275):238–9.PubMedCrossRef
7.
Zurück zum Zitat Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol. 2016;12(3):425–36.PubMedCrossRef Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol. 2016;12(3):425–36.PubMedCrossRef
8.
Zurück zum Zitat Wolin EM. Advances in the diagnosis and management of well-differentiated and intermediate-differentiated neuroendocrine tumors of the lung. Chest. 2016;151(5):1141–6.PubMedCrossRef Wolin EM. Advances in the diagnosis and management of well-differentiated and intermediate-differentiated neuroendocrine tumors of the lung. Chest. 2016;151(5):1141–6.PubMedCrossRef
9.
Zurück zum Zitat Ramirez RA, et al. Management of pulmonary neuroendocrine tumors. Rev Endocr Metab Disord. 2017;18(4):433–42.PubMedCrossRef Ramirez RA, et al. Management of pulmonary neuroendocrine tumors. Rev Endocr Metab Disord. 2017;18(4):433–42.PubMedCrossRef
11.
Zurück zum Zitat Litvak A, Pietanza MC. Bronchial and thymic carcinoid tumors. Hematol Oncol Clin North Am. 2016;30(1):83–102.PubMedCrossRef Litvak A, Pietanza MC. Bronchial and thymic carcinoid tumors. Hematol Oncol Clin North Am. 2016;30(1):83–102.PubMedCrossRef
12.
Zurück zum Zitat Phan AT, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39(6):784–98.PubMedCrossRef Phan AT, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39(6):784–98.PubMedCrossRef
13.
Zurück zum Zitat Weissferdt A, Moran CA. Neuroendocrine differentiation in thymic carcinomas: a diagnostic pitfall: an immunohistochemical analysis of 27 cases. Am J Clin Pathol. 2016;145(3):393–400.PubMedCrossRef Weissferdt A, Moran CA. Neuroendocrine differentiation in thymic carcinomas: a diagnostic pitfall: an immunohistochemical analysis of 27 cases. Am J Clin Pathol. 2016;145(3):393–400.PubMedCrossRef
14.
Zurück zum Zitat Oberg K, et al. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii120–3.PubMedCrossRef Oberg K, et al. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii120–3.PubMedCrossRef
15.
Zurück zum Zitat Kloppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2011;18(Suppl 1):S1–16.PubMedCrossRef Kloppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2011;18(Suppl 1):S1–16.PubMedCrossRef
16.
Zurück zum Zitat Viudez A, et al. Pancreatic neuroendocrine tumors: challenges in an underestimated disease. Crit Rev Oncol Hematol. 2016;101:193–206.PubMedCrossRef Viudez A, et al. Pancreatic neuroendocrine tumors: challenges in an underestimated disease. Crit Rev Oncol Hematol. 2016;101:193–206.PubMedCrossRef
17.
Zurück zum Zitat Vortmeyer AO, et al. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. 2004;89(4):1934–8.PubMedCrossRef Vortmeyer AO, et al. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. 2004;89(4):1934–8.PubMedCrossRef
18.
Zurück zum Zitat Anlauf M, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006;30(5):560–74.PubMedCrossRef Anlauf M, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006;30(5):560–74.PubMedCrossRef
19.
Zurück zum Zitat Morita M, et al. Conversion to neuroendocrine carcinoma from squamous cell carcinoma of the esophagus after definitive chemoradiotherapy. Anticancer Res. 2016;36(8):4045–9.PubMed Morita M, et al. Conversion to neuroendocrine carcinoma from squamous cell carcinoma of the esophagus after definitive chemoradiotherapy. Anticancer Res. 2016;36(8):4045–9.PubMed
21.
Zurück zum Zitat Scherubl H, et al. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy. 2010;42(8):664–71.PubMedCrossRef Scherubl H, et al. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy. 2010;42(8):664–71.PubMedCrossRef
22.
Zurück zum Zitat Capelli P, Fassan M, Scarpa A. Pathology - grading and staging of GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26(6):705–17.PubMedCrossRef Capelli P, Fassan M, Scarpa A. Pathology - grading and staging of GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26(6):705–17.PubMedCrossRef
23.
Zurück zum Zitat de Herder WW. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). Eur J Endocrinol. 2014;170(5):R173–83.PubMedCrossRef de Herder WW. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). Eur J Endocrinol. 2014;170(5):R173–83.PubMedCrossRef
24.
Zurück zum Zitat Kidd M, et al. Decoding the molecular and mutational ambiguities of gastroenteropancreatic neuroendocrine neoplasm pathobiology. Cell Mol Gastroenterol Hepatol. 2015;1(2):131–53.PubMedPubMedCentralCrossRef Kidd M, et al. Decoding the molecular and mutational ambiguities of gastroenteropancreatic neuroendocrine neoplasm pathobiology. Cell Mol Gastroenterol Hepatol. 2015;1(2):131–53.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2011;8(1):54–64.PubMedCrossRef Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2011;8(1):54–64.PubMedCrossRef
26.
Zurück zum Zitat Niederle B, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–38.PubMedCrossRef Niederle B, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–38.PubMedCrossRef
27.
Zurück zum Zitat Singer J, et al. Ectopic Cushing's syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum. Exp Clin Endocrinol Diabetes. 2010;118(8):524–9.PubMedCrossRef Singer J, et al. Ectopic Cushing's syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum. Exp Clin Endocrinol Diabetes. 2010;118(8):524–9.PubMedCrossRef
28.
Zurück zum Zitat Kojima M, et al. Neuroendocrine tumors of the large intestine: Clinicopathological features and predictive factors of lymph node metastasis. Front Oncol. 2016;6:173.PubMedPubMedCentralCrossRef Kojima M, et al. Neuroendocrine tumors of the large intestine: Clinicopathological features and predictive factors of lymph node metastasis. Front Oncol. 2016;6:173.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Pape UF, et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology. 2016;103(2):144–52.PubMedCrossRef Pape UF, et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology. 2016;103(2):144–52.PubMedCrossRef
30.
Zurück zum Zitat Vortmeyer AO, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst. 1997;89(19):1448–53.PubMedCrossRef Vortmeyer AO, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst. 1997;89(19):1448–53.PubMedCrossRef
31.
Zurück zum Zitat Ramage JK, et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139–43.PubMedCrossRef Ramage JK, et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139–43.PubMedCrossRef
33.
Zurück zum Zitat Chauhan A, et al. Transition of a pancreatic neuroendocrine tumor from ghrelinoma to insulinoma: a case report. J Gastrointest Oncol. 2015;6(2):E34–6.PubMedPubMedCentral Chauhan A, et al. Transition of a pancreatic neuroendocrine tumor from ghrelinoma to insulinoma: a case report. J Gastrointest Oncol. 2015;6(2):E34–6.PubMedPubMedCentral
34.
Zurück zum Zitat Wells SA Jr, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.PubMedPubMedCentralCrossRef Wells SA Jr, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Voss RK, et al. Medullary thyroid carcinoma in MEN2A: ATA moderate- or high-risk RET mutations do not predict disease aggressiveness. J Clin Endocrinol Metab. 2017;102(8):2807–13.PubMedPubMedCentralCrossRef Voss RK, et al. Medullary thyroid carcinoma in MEN2A: ATA moderate- or high-risk RET mutations do not predict disease aggressiveness. J Clin Endocrinol Metab. 2017;102(8):2807–13.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Raue F, et al. Long-term survivorship in multiple endocrine neoplasia type 2B diagnosed before and in the new millennium. J Clin Endocrinol Metab. 2018;103(1):235–43.PubMedCrossRef Raue F, et al. Long-term survivorship in multiple endocrine neoplasia type 2B diagnosed before and in the new millennium. J Clin Endocrinol Metab. 2018;103(1):235–43.PubMedCrossRef
37.
Zurück zum Zitat DeLellis RA, et al. Medullary thyroid carcinoma. In: Lloyd R, Osamura RY, Kloppel G, Rosai J, editors. WHO classification of Tumours of endocrine organs. 4th ed. Lyon: IARC; 2017. p. 108–13. DeLellis RA, et al. Medullary thyroid carcinoma. In: Lloyd R, Osamura RY, Kloppel G, Rosai J, editors. WHO classification of Tumours of endocrine organs. 4th ed. Lyon: IARC; 2017. p. 108–13.
38.
Zurück zum Zitat Eloy C, et al. Small cell tumors of the thyroid gland: a review. Int J Surg Pathol. 2014;22(3):197–201.PubMedCrossRef Eloy C, et al. Small cell tumors of the thyroid gland: a review. Int J Surg Pathol. 2014;22(3):197–201.PubMedCrossRef
39.
Zurück zum Zitat Starker LF, et al. Expression and somatic mutations of SDHAF2 (SDH5), a novel endocrine tumor suppressor gene in parathyroid tumors of primary hyperparathyroidism. Endocrine. 2010;38(3):397–401.PubMedCrossRef Starker LF, et al. Expression and somatic mutations of SDHAF2 (SDH5), a novel endocrine tumor suppressor gene in parathyroid tumors of primary hyperparathyroidism. Endocrine. 2010;38(3):397–401.PubMedCrossRef
40.
Zurück zum Zitat Matias-Guiu X, et al. Paraganglioma and mesenchymal/stromal tumours. In: Lloyd R, Osamura RY, Kloppel G, Rosai J, editors. WHO Classification of Tumours of Endocrine Organs, 4th ed. Lyon: IARC; 2017. p. 127. Matias-Guiu X, et al. Paraganglioma and mesenchymal/stromal tumours. In: Lloyd R, Osamura RY, Kloppel G, Rosai J, editors. WHO Classification of Tumours of Endocrine Organs, 4th ed. Lyon: IARC; 2017. p. 127.
41.
Zurück zum Zitat DeLellis RA, Erickson LA, Thompson LDR. Secondary, mesenchymal and other tumours. In: Lloyd R, Osamura RY, Kloppel G, Rosai J, editors. WHO Classification of Tumours of Endocrine Organs, 4th ed. Lyon: IARC; 2017. p. 159. DeLellis RA, Erickson LA, Thompson LDR. Secondary, mesenchymal and other tumours. In: Lloyd R, Osamura RY, Kloppel G, Rosai J, editors. WHO Classification of Tumours of Endocrine Organs, 4th ed. Lyon: IARC; 2017. p. 159.
42.
Zurück zum Zitat Strosberg JR. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol. 2013;40(1):120–33.PubMedCrossRef Strosberg JR. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol. 2013;40(1):120–33.PubMedCrossRef
43.
Zurück zum Zitat Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11(2):101–11.PubMedCrossRef Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11(2):101–11.PubMedCrossRef
44.
Zurück zum Zitat Pacak K, Teila SH. Pheochromocytoma and paraganglioma. In: De Groot LJ, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2018. Pacak K, Teila SH. Pheochromocytoma and paraganglioma. In: De Groot LJ, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2018.
45.
Zurück zum Zitat Kimura N, et al. Tumours of the adrenal medulla and extraadrenal paraganglia. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J, editors. WHO classification of Tumours of endocrine organs. 4th ed. Lyon: IARC; 2017. p. 179–206. Kimura N, et al. Tumours of the adrenal medulla and extraadrenal paraganglia. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J, editors. WHO classification of Tumours of endocrine organs. 4th ed. Lyon: IARC; 2017. p. 179–206.
46.
Zurück zum Zitat Tischler AS, de Krijger RR. Phaeochromocytoma. In: Lloyd R, Osamura RY, Kloppel G, Rosai J, editors. WHO Classification of Tumors of Endocrine Organs, 4h ed. Lyon: IARC; 2017. p. 183–9. Tischler AS, de Krijger RR. Phaeochromocytoma. In: Lloyd R, Osamura RY, Kloppel G, Rosai J, editors. WHO Classification of Tumors of Endocrine Organs, 4h ed. Lyon: IARC; 2017. p. 183–9.
47.
Zurück zum Zitat Kimura N, Capella C. Extraadrenal paraganglioma. In: Lloyd R, Osamura RY, Kloppel G, Rosai J, editors. WHO classification of Tumours of endocrine organs. 4th ed. Lyon: IARC; 2017. p. 190–5. Kimura N, Capella C. Extraadrenal paraganglioma. In: Lloyd R, Osamura RY, Kloppel G, Rosai J, editors. WHO classification of Tumours of endocrine organs. 4th ed. Lyon: IARC; 2017. p. 190–5.
49.
Zurück zum Zitat Kouba E, Cheng L. Neuroendocrine tumors of the urinary bladder according to the 2016 World Health Organization classification: molecular and clinical characteristics. Endocr Pathol. 2016;27(3):188–99.PubMedCrossRef Kouba E, Cheng L. Neuroendocrine tumors of the urinary bladder according to the 2016 World Health Organization classification: molecular and clinical characteristics. Endocr Pathol. 2016;27(3):188–99.PubMedCrossRef
50.
Zurück zum Zitat Priemer DS, et al. Neuroendocrine tumors of the prostate: emerging insights from molecular data and updates to the 2016 World Health Organization classification. Endocr Pathol. 2016;27(2):123–35.PubMedCrossRef Priemer DS, et al. Neuroendocrine tumors of the prostate: emerging insights from molecular data and updates to the 2016 World Health Organization classification. Endocr Pathol. 2016;27(2):123–35.PubMedCrossRef
51.
Zurück zum Zitat Kwon YS, Im KS, Choi DI. Ovarian large cell neuroendocrine carcinoma in the youngest woman. Eur J Gynaecol Oncol. 2016;37(2):244–6.PubMed Kwon YS, Im KS, Choi DI. Ovarian large cell neuroendocrine carcinoma in the youngest woman. Eur J Gynaecol Oncol. 2016;37(2):244–6.PubMed
53.
Zurück zum Zitat Ganesan R, et al. Neuroendocrine carcinoma of the cervix: review of a series of cases and correlation with outcome. Int J Surg Pathol. 2016;24(6):490–6.PubMedCrossRef Ganesan R, et al. Neuroendocrine carcinoma of the cervix: review of a series of cases and correlation with outcome. Int J Surg Pathol. 2016;24(6):490–6.PubMedCrossRef
54.
Zurück zum Zitat Koch CA, et al. Carcinoid syndrome caused by an atypical carcinoid of the uterine cervix. J Clin Endocrinol Metab. 1999;84(11):4209–13.PubMedCrossRef Koch CA, et al. Carcinoid syndrome caused by an atypical carcinoid of the uterine cervix. J Clin Endocrinol Metab. 1999;84(11):4209–13.PubMedCrossRef
55.
Zurück zum Zitat Adams RW, Dyson P, Barthelmes L. Neuroendocrine breast tumours: breast cancer or neuroendocrine cancer presenting in the breast? Breast. 2014;23(2):120–7.PubMedCrossRef Adams RW, Dyson P, Barthelmes L. Neuroendocrine breast tumours: breast cancer or neuroendocrine cancer presenting in the breast? Breast. 2014;23(2):120–7.PubMedCrossRef
56.
Zurück zum Zitat Asioli S, et al. Working formulation of neuroendocrine tumors of the skin and breast. Endocr Pathol. 2014;25(2):141–50.PubMedCrossRef Asioli S, et al. Working formulation of neuroendocrine tumors of the skin and breast. Endocr Pathol. 2014;25(2):141–50.PubMedCrossRef
57.
Zurück zum Zitat Lubana SS, et al. Primary neuroendocrine tumor (carcinoid tumor) of the testis: a case report with review of literature. Am J Case Rep. 2015;16:328–32.PubMedPubMedCentralCrossRef Lubana SS, et al. Primary neuroendocrine tumor (carcinoid tumor) of the testis: a case report with review of literature. Am J Case Rep. 2015;16:328–32.PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Aung PP, et al. Primary neuroendocrine tumors of the kidney: morphological and molecular alterations of an uncommon malignancy. Hum Pathol. 2013;44(5):873–80.PubMedCrossRef Aung PP, et al. Primary neuroendocrine tumors of the kidney: morphological and molecular alterations of an uncommon malignancy. Hum Pathol. 2013;44(5):873–80.PubMedCrossRef
59.
Zurück zum Zitat Yamagata K, et al. A rare primary neuroendocrine tumor (typical carcinoid) of the sublingual gland. Case Rep Dent. 2016;7462690:2016. Yamagata K, et al. A rare primary neuroendocrine tumor (typical carcinoid) of the sublingual gland. Case Rep Dent. 2016;7462690:2016.
60.
Zurück zum Zitat Iype S, et al. Neuroendocrine tumours of the gallbladder: three cases and a review of the literature. Postgrad Med J. 2009;85(1002):213–8.PubMedCrossRef Iype S, et al. Neuroendocrine tumours of the gallbladder: three cases and a review of the literature. Postgrad Med J. 2009;85(1002):213–8.PubMedCrossRef
61.
Zurück zum Zitat Thar YY, et al. An extremely rare case of advanced metastatic small cell neuroendocrine carcinoma of sinonasal tract. Case Rep Oncol Med. 2016;1496916:2016. Thar YY, et al. An extremely rare case of advanced metastatic small cell neuroendocrine carcinoma of sinonasal tract. Case Rep Oncol Med. 2016;1496916:2016.
62.
Zurück zum Zitat Coriat R, et al. Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement. Oncologist. 2016;21(10):1191–9.PubMedPubMedCentralCrossRef Coriat R, et al. Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement. Oncologist. 2016;21(10):1191–9.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat de Mestier L, et al. Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms. Neuroendocrinology. 2017;105(4):412–25.PubMedCrossRef de Mestier L, et al. Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms. Neuroendocrinology. 2017;105(4):412–25.PubMedCrossRef
64.
Zurück zum Zitat Scoazec JY, Couvelard A. Classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann Pathol. 2017;37(6):444–56.PubMedCrossRef Scoazec JY, Couvelard A. Classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann Pathol. 2017;37(6):444–56.PubMedCrossRef
65.
Zurück zum Zitat Travis WD, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.CrossRefPubMed Travis WD, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.CrossRefPubMed
66.
Zurück zum Zitat Caplin ME, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–20.PubMedCrossRef Caplin ME, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–20.PubMedCrossRef
67.
Zurück zum Zitat Inzani F, et al. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord. 2017;18(4):381–91.PubMedCrossRef Inzani F, et al. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord. 2017;18(4):381–91.PubMedCrossRef
68.
Zurück zum Zitat Nunez-Valdovinos B, et al. Neuroendocrine tumor heterogeneity adds uncertainty to the World Health Organization 2010 classification: real-world data from the Spanish tumor registry (R-GETNE). Oncologist. 2018;23(4):422–32.PubMedCrossRefPubMedCentral Nunez-Valdovinos B, et al. Neuroendocrine tumor heterogeneity adds uncertainty to the World Health Organization 2010 classification: real-world data from the Spanish tumor registry (R-GETNE). Oncologist. 2018;23(4):422–32.PubMedCrossRefPubMedCentral
69.
Zurück zum Zitat Trantakis C, et al. Acromegaly caused by a thoracic neuroendocrine tumor. Exp Clin Endocrinol Diabetes. 2005:113–58. Trantakis C, et al. Acromegaly caused by a thoracic neuroendocrine tumor. Exp Clin Endocrinol Diabetes. 2005:113–58.
70.
Zurück zum Zitat Koch CA. Cushing's syndrome and glucocorticoid excess. In: Berbari AE, Mancia G, editors. Disorders of blood pressure regulation. New York: Springer; 2018. p. 481–512.CrossRef Koch CA. Cushing's syndrome and glucocorticoid excess. In: Berbari AE, Mancia G, editors. Disorders of blood pressure regulation. New York: Springer; 2018. p. 481–512.CrossRef
71.
Zurück zum Zitat Falconi M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.PubMedCrossRef Falconi M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.PubMedCrossRef
72.
Zurück zum Zitat Vinik A. Diffuse hormonal systems. In: De Groot LJ, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2017. Vinik A. Diffuse hormonal systems. In: De Groot LJ, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2017.
73.
Zurück zum Zitat Vinik A, et al. Carcinoid tumors. In: De Groot LJ, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2018. Vinik A, et al. Carcinoid tumors. In: De Groot LJ, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2018.
74.
Zurück zum Zitat Amin S, Kim MK. Islet cell tumors of the pancreas. Gastroenterol Clin N Am. 2016;45(1):83–100.CrossRef Amin S, Kim MK. Islet cell tumors of the pancreas. Gastroenterol Clin N Am. 2016;45(1):83–100.CrossRef
75.
Zurück zum Zitat Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: advances in diagnosis and management. World J Gastroenterol. 2015;21(32):9512–25.PubMedPubMedCentralCrossRef Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: advances in diagnosis and management. World J Gastroenterol. 2015;21(32):9512–25.PubMedPubMedCentralCrossRef
76.
Zurück zum Zitat Boutzios G, Kaltsas G. Clinical syndromes related to gastrointestinal neuroendocrine neoplasms. Front Horm Res. 2015;44:40–57.PubMedCrossRef Boutzios G, Kaltsas G. Clinical syndromes related to gastrointestinal neuroendocrine neoplasms. Front Horm Res. 2015;44:40–57.PubMedCrossRef
77.
Zurück zum Zitat Dimitriadis GK, et al. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23(9):R423–36.PubMedCrossRef Dimitriadis GK, et al. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23(9):R423–36.PubMedCrossRef
78.
Zurück zum Zitat Verbeek WH, Korse CM, Tesselaar ME. GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers. Eur J Endocrinol. 2016;174(1):R1–7.PubMedCrossRef Verbeek WH, Korse CM, Tesselaar ME. GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers. Eur J Endocrinol. 2016;174(1):R1–7.PubMedCrossRef
79.
Zurück zum Zitat Luis SA, Pellikka PA. Carcinoid heart disease: diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2016;30(1):149–58.PubMedCrossRef Luis SA, Pellikka PA. Carcinoid heart disease: diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2016;30(1):149–58.PubMedCrossRef
80.
Zurück zum Zitat Halperin DM, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–34.PubMedPubMedCentralCrossRef Halperin DM, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–34.PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Granberg D. Biochemical testing in patients with neuroendocrine tumors. Front Horm Res. 2015;44:24–39.PubMedCrossRef Granberg D. Biochemical testing in patients with neuroendocrine tumors. Front Horm Res. 2015;44:24–39.PubMedCrossRef
82.
Zurück zum Zitat Skrabanek P, et al. Substance P secretion by carcinoid tumours. Ir J Med Sci. 1978;147(2):47–9.PubMedCrossRef Skrabanek P, et al. Substance P secretion by carcinoid tumours. Ir J Med Sci. 1978;147(2):47–9.PubMedCrossRef
84.
Zurück zum Zitat Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options in Oncol. 2014;15(3):365–79.CrossRef Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options in Oncol. 2014;15(3):365–79.CrossRef
85.
Zurück zum Zitat Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35.PubMedCrossRef Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35.PubMedCrossRef
86.
Zurück zum Zitat Starker LF, Carling T. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Curr Opin Oncol. 2009;21(1):29–33.PubMedCrossRef Starker LF, Carling T. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Curr Opin Oncol. 2009;21(1):29–33.PubMedCrossRef
87.
Zurück zum Zitat Perren A, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol. 2000;157(4):1097–103.PubMedPubMedCentralCrossRef Perren A, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol. 2000;157(4):1097–103.PubMedPubMedCentralCrossRef
89.
Zurück zum Zitat Sunaga N, et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther. 2011;10(2):336–46.PubMedPubMedCentralCrossRef Sunaga N, et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther. 2011;10(2):336–46.PubMedPubMedCentralCrossRef
90.
Zurück zum Zitat Lea IA, et al. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis. 2007;28(9):1851–8.PubMedCrossRef Lea IA, et al. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis. 2007;28(9):1851–8.PubMedCrossRef
93.
Zurück zum Zitat Dorantes-Heredia R, Ruiz-Morales JM, Cano-Garcia F. Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. Transl Lung Cancer Res. 2016;5(4):401–12.PubMedPubMedCentralCrossRef Dorantes-Heredia R, Ruiz-Morales JM, Cano-Garcia F. Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. Transl Lung Cancer Res. 2016;5(4):401–12.PubMedPubMedCentralCrossRef
94.
Zurück zum Zitat Crona J, Skogseid B. GEP- NETS UPDATE: genetics of neuroendocrine tumors. Eur J Endocrinol. 2016;174(6):R275–90.PubMedCrossRef Crona J, Skogseid B. GEP- NETS UPDATE: genetics of neuroendocrine tumors. Eur J Endocrinol. 2016;174(6):R275–90.PubMedCrossRef
95.
Zurück zum Zitat Yates CJ, Newey PJ, Thakker RV. Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol. 2015;3(11):895–905.PubMedCrossRef Yates CJ, Newey PJ, Thakker RV. Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol. 2015;3(11):895–905.PubMedCrossRef
96.
Zurück zum Zitat Wells SA Jr, et al. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 2013;98(8):3149–64.PubMedPubMedCentralCrossRef Wells SA Jr, et al. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 2013;98(8):3149–64.PubMedPubMedCentralCrossRef
97.
Zurück zum Zitat Brauer VF, et al. RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed? Endocr Pract. 2004;10(1):5–9.PubMedCrossRef Brauer VF, et al. RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed? Endocr Pract. 2004;10(1):5–9.PubMedCrossRef
98.
99.
Zurück zum Zitat Uccella S, et al. Immunohistochemical biomarkers of gastrointestinal, pancreatic, pulmonary, and thymic neuroendocrine neoplasms. Endocr Pathol. 2018;29(2):150–68.PubMedCrossRef Uccella S, et al. Immunohistochemical biomarkers of gastrointestinal, pancreatic, pulmonary, and thymic neuroendocrine neoplasms. Endocr Pathol. 2018;29(2):150–68.PubMedCrossRef
100.
Zurück zum Zitat Delle Fave G, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119–24.PubMedCrossRef Delle Fave G, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119–24.PubMedCrossRef
101.
Zurück zum Zitat Garcia-Carbonero R, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94.PubMedCrossRef Garcia-Carbonero R, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94.PubMedCrossRef
102.
Zurück zum Zitat Chan DL, et al. Prognostic and predictive biomarkers in neuroendocrine tumours. Crit Rev Oncol Hematol. 2017;113:268–82.PubMedCrossRef Chan DL, et al. Prognostic and predictive biomarkers in neuroendocrine tumours. Crit Rev Oncol Hematol. 2017;113:268–82.PubMedCrossRef
103.
Zurück zum Zitat Moreira RK, Washington K. Pathology of gastrointestinal neuroendocrine tumors: an update. Surg Pathol Clin. 2010;3(2):327–47.PubMedCrossRef Moreira RK, Washington K. Pathology of gastrointestinal neuroendocrine tumors: an update. Surg Pathol Clin. 2010;3(2):327–47.PubMedCrossRef
104.
Zurück zum Zitat Auernhammer CJ, et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol. 2018;6(5):404–15.PubMedCrossRef Auernhammer CJ, et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol. 2018;6(5):404–15.PubMedCrossRef
105.
Zurück zum Zitat Oberg K, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology. 2017;105(3):201–11.PubMedCrossRef Oberg K, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology. 2017;105(3):201–11.PubMedCrossRef
106.
Zurück zum Zitat Mafficini A, Scarpa A. Genomic landscape of pancreatic neuroendocrine tumours: the international cancer genome consortium. J Endocrinol. 2018;236(3):R161–7.PubMedPubMedCentralCrossRef Mafficini A, Scarpa A. Genomic landscape of pancreatic neuroendocrine tumours: the international cancer genome consortium. J Endocrinol. 2018;236(3):R161–7.PubMedPubMedCentralCrossRef
108.
Zurück zum Zitat Jiao Y, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203.PubMedPubMedCentralCrossRef Jiao Y, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203.PubMedPubMedCentralCrossRef
109.
Zurück zum Zitat Scarpa A, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71.PubMedCrossRef Scarpa A, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71.PubMedCrossRef
110.
Zurück zum Zitat Fishbein L, et al. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6140.PubMedCrossRef Fishbein L, et al. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6140.PubMedCrossRef
111.
Zurück zum Zitat Dreijerink KMA, Timmers HTM, Brown M. Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1. Endocr Relat Cancer. 2017;24(10):T135–45.PubMedPubMedCentralCrossRef Dreijerink KMA, Timmers HTM, Brown M. Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1. Endocr Relat Cancer. 2017;24(10):T135–45.PubMedPubMedCentralCrossRef
112.
Zurück zum Zitat Capdevila J, et al. Translational research in neuroendocrine tumors: pitfalls and opportunities. Oncogene. 2016;36(14):1899–907.PubMedCrossRef Capdevila J, et al. Translational research in neuroendocrine tumors: pitfalls and opportunities. Oncogene. 2016;36(14):1899–907.PubMedCrossRef
114.
Zurück zum Zitat Else T. 15 YEARS OF PARAGANGLIOMA: Pheochromocytoma, paraganglioma and genetic syndromes: a historical perspective. Endocr Relat Cancer. 2015;22(4):T147–59.PubMedCrossRef Else T. 15 YEARS OF PARAGANGLIOMA: Pheochromocytoma, paraganglioma and genetic syndromes: a historical perspective. Endocr Relat Cancer. 2015;22(4):T147–59.PubMedCrossRef
115.
Zurück zum Zitat Comino-Mendez I, et al. ATRX driver mutation in a composite malignant pheochromocytoma. Cancer Genet. 2016;209(6):272–7.PubMedCrossRef Comino-Mendez I, et al. ATRX driver mutation in a composite malignant pheochromocytoma. Cancer Genet. 2016;209(6):272–7.PubMedCrossRef
116.
Zurück zum Zitat Ladd-Acosta C, Fallin MD. The role of epigenetics in genetic and environmental epidemiology. Epigenomics. 2016;8(2):271–83.PubMedCrossRef Ladd-Acosta C, Fallin MD. The role of epigenetics in genetic and environmental epidemiology. Epigenomics. 2016;8(2):271–83.PubMedCrossRef
117.
Zurück zum Zitat Karpathakis A, Dibra H, Thirlwell C. Neuroendocrine tumours: cracking the epigenetic code. Endocr Relat Cancer. 2013;20(3):R65–82.PubMedCrossRef Karpathakis A, Dibra H, Thirlwell C. Neuroendocrine tumours: cracking the epigenetic code. Endocr Relat Cancer. 2013;20(3):R65–82.PubMedCrossRef
118.
Zurück zum Zitat House MG, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg. 2003;238(3):423–31 discussion 431-2.PubMedPubMedCentralCrossRef House MG, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg. 2003;238(3):423–31 discussion 431-2.PubMedPubMedCentralCrossRef
119.
Zurück zum Zitat Pizzi S, et al. RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol. 2005;206(4):409–16.PubMedCrossRef Pizzi S, et al. RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol. 2005;206(4):409–16.PubMedCrossRef
120.
Zurück zum Zitat Liu L, et al. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform a and p16 genes are associated with metastasis. Mod Pathol. 2005;18(12):1632–40.PubMedCrossRef Liu L, et al. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform a and p16 genes are associated with metastasis. Mod Pathol. 2005;18(12):1632–40.PubMedCrossRef
121.
Zurück zum Zitat Dejeux E, et al. Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression. Endocr Relat Cancer. 2009;16(3):939–52.PubMedCrossRef Dejeux E, et al. Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression. Endocr Relat Cancer. 2009;16(3):939–52.PubMedCrossRef
122.
Zurück zum Zitat Chan AO, et al. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene. 2003;22(6):924–34.PubMedCrossRef Chan AO, et al. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene. 2003;22(6):924–34.PubMedCrossRef
123.
Zurück zum Zitat Mapelli P, et al. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. Oncogene. 2015;34(34):4439–47.PubMedCrossRef Mapelli P, et al. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. Oncogene. 2015;34(34):4439–47.PubMedCrossRef
124.
Zurück zum Zitat Pelosi G, et al. Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. Anticancer Res. 2010;30(10):4269–81.PubMed Pelosi G, et al. Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. Anticancer Res. 2010;30(10):4269–81.PubMed
125.
Zurück zum Zitat How-Kit A, et al. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors. Epigenomics. 2015;7(8):1245–58.PubMedCrossRef How-Kit A, et al. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors. Epigenomics. 2015;7(8):1245–58.PubMedCrossRef
126.
Zurück zum Zitat Modlin IM, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: from monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab. 2016;30(1):59–77.PubMedCrossRef Modlin IM, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: from monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab. 2016;30(1):59–77.PubMedCrossRef
127.
Zurück zum Zitat Vicentini C, et al. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract. Molecules. 2014;19(2):2458–68.PubMedCrossRefPubMedCentral Vicentini C, et al. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract. Molecules. 2014;19(2):2458–68.PubMedCrossRefPubMedCentral
128.
Zurück zum Zitat Roldo C, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24(29):4677–84.PubMedCrossRef Roldo C, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24(29):4677–84.PubMedCrossRef
129.
Zurück zum Zitat Ruebel K, et al. MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol. 2010;23(3):367–75.PubMedCrossRef Ruebel K, et al. MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol. 2010;23(3):367–75.PubMedCrossRef
130.
Zurück zum Zitat Amaral T, Leiter U, Garbe C. Merkel cell carcinoma: epidemiology, pathogenesis, diagnosis and therapy. Rev Endocr Metab Disord. 2017;18(4):517–32.PubMedCrossRef Amaral T, Leiter U, Garbe C. Merkel cell carcinoma: epidemiology, pathogenesis, diagnosis and therapy. Rev Endocr Metab Disord. 2017;18(4):517–32.PubMedCrossRef
131.
132.
Zurück zum Zitat Mairinger FD, et al. Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study. Mod Pathol. 2014;27(12):1632–40.PubMedCrossRef Mairinger FD, et al. Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study. Mod Pathol. 2014;27(12):1632–40.PubMedCrossRef
133.
Zurück zum Zitat Modali SD, et al. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol. 2015;29(2):224–37.PubMedPubMedCentralCrossRef Modali SD, et al. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol. 2015;29(2):224–37.PubMedPubMedCentralCrossRef
137.
Zurück zum Zitat Zhou HL, et al. Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms. Nucleic Acids Res. 2014;42(2):701–13.PubMedCrossRef Zhou HL, et al. Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms. Nucleic Acids Res. 2014;42(2):701–13.PubMedCrossRef
138.
Zurück zum Zitat Bechara EG, et al. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell. 2013;52(5):720–33.PubMedCrossRef Bechara EG, et al. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell. 2013;52(5):720–33.PubMedCrossRef
139.
Zurück zum Zitat Babic I, et al. EGFR mutation-induced alternative splicing of max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013;17(6):1000–8.PubMedPubMedCentralCrossRef Babic I, et al. EGFR mutation-induced alternative splicing of max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013;17(6):1000–8.PubMedPubMedCentralCrossRef
140.
Zurück zum Zitat Alsafadi S, et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016;7:10615.PubMedPubMedCentralCrossRef Alsafadi S, et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016;7:10615.PubMedPubMedCentralCrossRef
141.
Zurück zum Zitat Luque RM, et al. In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: evidence from clinical, cellular and molecular parameters. Oncotarget. 2015;6(23):19619–33.PubMedPubMedCentralCrossRef Luque RM, et al. In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: evidence from clinical, cellular and molecular parameters. Oncotarget. 2015;6(23):19619–33.PubMedPubMedCentralCrossRef
142.
Zurück zum Zitat Sampedro-Nunez M, et al. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget. 2016;7(6):6593–608.PubMedCrossRef Sampedro-Nunez M, et al. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget. 2016;7(6):6593–608.PubMedCrossRef
143.
Zurück zum Zitat Chaudhry A, et al. Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. Cancer Res. 1994;54(4):981–6.PubMed Chaudhry A, et al. Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. Cancer Res. 1994;54(4):981–6.PubMed
144.
Zurück zum Zitat Terris B, et al. Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours. Clin Mol Pathol. 1996;49(4):M203–8.PubMedPubMedCentralCrossRef Terris B, et al. Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours. Clin Mol Pathol. 1996;49(4):M203–8.PubMedPubMedCentralCrossRef
145.
Zurück zum Zitat Miyanaga A, et al. Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours. Ann Oncol. 2013;24(1):84–90.PubMedCrossRef Miyanaga A, et al. Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours. Ann Oncol. 2013;24(1):84–90.PubMedCrossRef
146.
Zurück zum Zitat Edmond V, et al. A new function of the splicing factor SRSF2 in the control of E2F1-mediated cell cycle progression in neuroendocrine lung tumors. Cell Cycle. 2013;12(8):1267–78.PubMedPubMedCentralCrossRef Edmond V, et al. A new function of the splicing factor SRSF2 in the control of E2F1-mediated cell cycle progression in neuroendocrine lung tumors. Cell Cycle. 2013;12(8):1267–78.PubMedPubMedCentralCrossRef
147.
Zurück zum Zitat Cives M, Soares HP, Strosberg J. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol. 2016;28(4):359–66.PubMedCrossRef Cives M, Soares HP, Strosberg J. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol. 2016;28(4):359–66.PubMedCrossRef
148.
Zurück zum Zitat Rickman DS, et al. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med. 2017;23(6):1–10.PubMedCrossRef Rickman DS, et al. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med. 2017;23(6):1–10.PubMedCrossRef
149.
Zurück zum Zitat Cwikla JB, et al. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab. 2015;100(11):E1437–45.PubMedCrossRef Cwikla JB, et al. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab. 2015;100(11):E1437–45.PubMedCrossRef
150.
Zurück zum Zitat Bowden M, et al. Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma. Oncotarget. 2017;8(33):54331–44.PubMedPubMedCentralCrossRef Bowden M, et al. Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma. Oncotarget. 2017;8(33):54331–44.PubMedPubMedCentralCrossRef
151.
Zurück zum Zitat Kim ST, et al. Genomic profiling of metastatic gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in the personalized-medicine era. J Cancer. 2016;7(9):1044–8.PubMedPubMedCentralCrossRef Kim ST, et al. Genomic profiling of metastatic gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in the personalized-medicine era. J Cancer. 2016;7(9):1044–8.PubMedPubMedCentralCrossRef
152.
Zurück zum Zitat Young K, et al. Pancreatic neuroendocrine tumors: a review. Future Oncol. 2015;11(5):853–64.PubMedCrossRef Young K, et al. Pancreatic neuroendocrine tumors: a review. Future Oncol. 2015;11(5):853–64.PubMedCrossRef
153.
Zurück zum Zitat Li TT, et al. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol. 2014;20(1):118–25.PubMedPubMedCentralCrossRef Li TT, et al. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol. 2014;20(1):118–25.PubMedPubMedCentralCrossRef
154.
Zurück zum Zitat Pavel M, de Herder WW. ENETS consensus guidelines for the standard of care in neuroendocrine tumors. Neuroendocrinology. 2017;105(3):193–5.PubMedCrossRef Pavel M, de Herder WW. ENETS consensus guidelines for the standard of care in neuroendocrine tumors. Neuroendocrinology. 2017;105(3):193–5.PubMedCrossRef
155.
Zurück zum Zitat Kulke MH, et al. Neuroendocrine tumors. J Natl Compr Cancer Netw. 2012;10(6):724–64.CrossRef Kulke MH, et al. Neuroendocrine tumors. J Natl Compr Cancer Netw. 2012;10(6):724–64.CrossRef
156.
Zurück zum Zitat Pavel ME, Sers C. Women in cancer thematic review: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine. Endocr Relat Cancer. 2016;23(11):T135–54.PubMedCrossRef Pavel ME, Sers C. Women in cancer thematic review: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine. Endocr Relat Cancer. 2016;23(11):T135–54.PubMedCrossRef
157.
Zurück zum Zitat Pavel M, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85.PubMedCrossRef Pavel M, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85.PubMedCrossRef
158.
Zurück zum Zitat Modlin IM, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–88.PubMed Modlin IM, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–88.PubMed
159.
Zurück zum Zitat Berardi R, et al. Gastrointestinal neuroendocrine tumors: searching the optimal treatment strategy--a literature review. Crit Rev Oncol Hematol. 2016;98:264–74.PubMedCrossRef Berardi R, et al. Gastrointestinal neuroendocrine tumors: searching the optimal treatment strategy--a literature review. Crit Rev Oncol Hematol. 2016;98:264–74.PubMedCrossRef
160.
Zurück zum Zitat Kim SJ, et al. The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42(13):1964–70.PubMedCrossRef Kim SJ, et al. The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42(13):1964–70.PubMedCrossRef
161.
Zurück zum Zitat Parghane RV, et al. Clinical response profile of metastatic/advanced pulmonary neuroendocrine tumors to peptide receptor radionuclide therapy with 177Lu-DOTATATE. Clin Nucl Med. 2017;42(6):428–35.PubMedCrossRef Parghane RV, et al. Clinical response profile of metastatic/advanced pulmonary neuroendocrine tumors to peptide receptor radionuclide therapy with 177Lu-DOTATATE. Clin Nucl Med. 2017;42(6):428–35.PubMedCrossRef
162.
Zurück zum Zitat Castaño JP, et al. Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges. Cancer Metastasis Rev. 2014;33(1):353–9.PubMedCrossRef Castaño JP, et al. Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges. Cancer Metastasis Rev. 2014;33(1):353–9.PubMedCrossRef
163.
Zurück zum Zitat Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci. 2013;34(12):676–88.PubMedCrossRef Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci. 2013;34(12):676–88.PubMedCrossRef
164.
Zurück zum Zitat Herrera-Martinez AD, et al. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. Lung Cancer. 2017;109:128–36.PubMedCrossRef Herrera-Martinez AD, et al. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. Lung Cancer. 2017;109:128–36.PubMedCrossRef
165.
Zurück zum Zitat Herrera-Martinez AD, et al. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine. 2018;59(2):426–37.PubMedCrossRef Herrera-Martinez AD, et al. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine. 2018;59(2):426–37.PubMedCrossRef
166.
Zurück zum Zitat Mangano A, et al. New horizons for targeted treatment of neuroendocrine tumors. Future Oncol. 2016;12(8):1059–65.PubMedCrossRef Mangano A, et al. New horizons for targeted treatment of neuroendocrine tumors. Future Oncol. 2016;12(8):1059–65.PubMedCrossRef
167.
Zurück zum Zitat Oberg K, et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res. 2013;19(11):2842–9.PubMedCrossRef Oberg K, et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res. 2013;19(11):2842–9.PubMedCrossRef
169.
Zurück zum Zitat Raymond E, et al. Sunitinib in pancreatic neuroendocrine tumors. Target Oncol. 2012;7(2):117–25.PubMedCrossRef Raymond E, et al. Sunitinib in pancreatic neuroendocrine tumors. Target Oncol. 2012;7(2):117–25.PubMedCrossRef
Metadaten
Titel
Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors
verfasst von
Sergio Pedraza-Arévalo
Manuel D. Gahete
Emilia Alors-Pérez
Raúl M. Luque
Justo P. Castaño
Publikationsdatum
06.10.2018
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 2/2018
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-018-9465-0

Weitere Artikel der Ausgabe 2/2018

Reviews in Endocrine and Metabolic Disorders 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.